publication . Article . 2016

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Castellsagué, Xavier; Ault, Kevin A.; Bosch, F. Xavier; Brown, Darron; Cuzick, Jack; Ferris, Daron G.; Joura, Elmar A.; Garland, Suzanne M.; Giuliano, Anna R; Hernandez-Avila, Mauricio; ...
Open Access
  • Published: 01 Dec 2016 Journal: Papillomavirus Research, volume 2, pages 61-69 (issn: 2405-8521, Copyright policy)
  • Publisher: Elsevier BV
Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region Methods: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation ...
free text keywords: Papil·lomavirus, Càncer de coll uterí, Papillomaviruses, Cervix cancer, Adenocarcinoma in situ, Enfermedades, Papiloma, Neoplasmas, Wart Virus Vaccine, Age Distribution, Article, Condyloma Acuminatum, Geographic Distribution, Health Program, Human, Human Papillomavirus Type 11, Human Papillomavirus Type 16, Human Papillomavirus Type 18, Human Papillomavirus Type 31, Human Papillomavirus Type 33, Human Papillomavirus Type 45, Human Papillomavirus Type 52, Human Papillomavirus Type 58, Human Papillomavirus Type 6, Immunization, Infection Risk, Mixed Infection, Molecular Epidemiology, Nonhuman, Prevalence, Priority Journal, Systematic Review, Uterine Cervix Carcinoma In Situ, Virus Detection, Wart Virus, Adenocarcinoma, Adolescent, Adult, Asia, Classification, Europe, Female, Genetics, Isolation And Purification, Middle Aged, North America, Randomized Controlled Trial (Topic), South And Central America, Virology, Humans, Latin America, Randomized Controlled Trials As Topic, Papillomaviridae, biology.organism_classification, biology, Koilocyte, Human papillomavirus, Gynecology, medicine.medical_specialty, medicine, Intraepithelial neoplasia, Cervical intraepithelial neoplasia, medicine.disease, business.industry, business, Genotype, Young adult, Cervical cancer, Infectious and parasitic diseases, RC109-216
29 references, page 1 of 2

Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J.. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med.. 2015; 372: 711-723 [OpenAIRE] [PubMed]

International Agency for Research on Cancer, null. 2012

Serrano, B., Alemany, L., Tous, S., Bruni, L., Clifford, G.M., Weiss, T.. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agent Cancer. 2012; 7: 38 [OpenAIRE] [PubMed]

Joura, E.A., Ault, K.A., Bosch, F.X., Brown, D., Cuzick, J., Ferris, D.. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol. Biomark. Prev.. 2014; 23: 1997-2008

Goldie, S.J., O’Shea, M., Diaz, M., Kim, S.Y.. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod. Health Matters. 2008; 16: 86-96 [PubMed]

Brotherton, J.M., Gertig, D.M.. Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Rev. Anti Infect. Ther.. 2011; 9: 627-639 [OpenAIRE] [PubMed]

Serrano, B., Alemany, L., Ruiz, P.A., Tous, S., Lima, M.A., Bruni, L.. Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiol.. 2014; 38: 748-756 [PubMed]

Garland, S.M., Hernandez-Avila, M., Wheeler, C.M., Perez, G., Harper, D.M., Leodolter, S.. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med.. 2007; 356: 1928-1943 [OpenAIRE] [PubMed]

FUTURE II Study Group, null. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.. 2007; 356: 1915-1927 [PubMed]

Munoz, N., Manalastas, R., Pitisuttihum, P., Tresukosol, D., Monsonego, J., Ault, K.. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet. 2009; 373: 1949-1957 [OpenAIRE] [PubMed]

Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K.. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br. J. Cancer. 2011; 105: 28-37 [OpenAIRE] [PubMed]

12 International Patent Numbers WO 2003/019143 A2, WO 2006/116276 A2, and WO 2006/116303 A2. 〈http://www.wipo int/portal/index html〉. (accessed 21.02.11).

Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Ault, K.A., Giuliano, A.R.. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol.. 2005; 6: 271-278 [PubMed]

Mao, C., Koutsky, L.A., Ault, K.A., Wheeler, C.M., Brown, D.R., Wiley, D.J.. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.. 2006; 107: 18-27 [OpenAIRE] [PubMed]

Sahasrabuddhe, V.V., Castle, P.E., Follansbee, S., Borgonovo, S., Tokugawa, D., Schwartz, L.M.. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J. Infect. Dis.. 2013; 207: 392-401 [OpenAIRE] [PubMed]

29 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue